top of page

22nd November 2018

Emily and Anu CI Annual Conference.jpg

Two of the team's Clinical Research Fellows, Anu and Emily, presented their work at the Cancer Institute's Annual Conference. They also took part in the one minute flash talks. A challenging but exciting way to share their projects with a wider audience across the Institute.

18th October 2018

We are delighted to announce that we are part of the MRC funded ReIMAGINE study, which will test for the first time if MRI scans can be used for population screening to detect prostate cancer more accurately. The project will combine the underlying molecular changes in the cancer with state-of-the-art imaging. This will allow the prediction of prostate cancer status for the individual (low, medium or high risk) without recourse to biopsy. It will also allow prediction of which prostate cancers are likely to progress over time and which are not, which has largely eluded scientists so far. By doing so, men will be subject to fewer but better biopsies, improved risk stratification, appropriate treatment allocation, more benefit, less harm and more cost-effective care.


Our team will lead Work Strand 4 (WS4), which is the analysis of genomic, transcriptomic, epigenetic, immune/inflammatory data from tumour cores, blood and urine.

More information can be found here

29th September 2018

Anjui, PhD student, Daniel and Marina, both Senior Research Fellows, welcomed CRUK supporters for lab tours during the Institute's Open Day. Anjui explained the concept and applications of liquid biopsy, Daniel talked about the group's work on single cells and Marina talked about the STRATOSPHERE project. Some participants were also able to try their hand at pipetting. 

A wonderful opportunity to share our work with supporters and thank them for their hard work in fundraising.


20th September 2018

The group, alongside close collaborator Francesca Demichelis (@FrancescaBZNY) at the University of Trento, Italy, has received funding through an Accelerator Award from CRUK (Cancer Research UK) and AIRC (Associazione Italiana per la Ricerca sul Cancro) to develop novel tools to analyse liquid biopsies.


PRIME (Prostate cancer plasma Integrative multimodal evaluation) aims to maximise the amount of information that can be generated from liquid biopsies, expanding their clinical uses in molecular stratification, treatment selection, and monitoring resistance.


The project will make use of the high-quality liquid biopsies from clinical trials of advanced prostate cancer, including the UK-wide, practice-changing STAMPEDE clinical trial for men starting long-term life-prolonging hormone therapies.This gives the team access to cases representative of the whole spectrum of advanced prostate cancer, including hormone-sensitive disease and through to men who have developed treatment resistance.

More information is available here:

14th September 2018

Emily, Clinical Research Fellow, (@EmilyGrist1) and Marina, Senior Research Fellow, (@Marina_Parry) attended the Molecular Analysis for Personalised Therapy (MAP) Conference in Paris ( and presented preliminary work on the STRATOSPHERE project, funded by PCUK. 

bottom of page